一种新且独立的OSCC生存预后模型:RNA结合蛋白的功能和预后值
Shanshan Wang1, Shuang Liu2, Yaomin Zhu1
1Shenzhen Stomatology Hospital, Shenzhen, 518001, Guangdong, People's Republic of China.
概括
使用九种RNA结合蛋白 (RBPs) 的新模型可以预测口腔状细胞癌 (OSCC) 患者的结果. 这种RBP签名为预后提供了可靠的生物标志物,并指导临床治疗决策.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 生物信息学是一种生物信息学.
背景情况:
- 口腔状细胞癌 (OSCC) 是一种流行且具有攻击性的癌症.
- RNA结合蛋白 (RBPs) 的异常表达与癌症的发展和进展有关.
研究的目的:
- 根据RBPs开发和验证OSCC的预后评估模型.
- 为了评估RBPs在OSCC患者的预后价值.
主要方法:
- 从TCGA和GEO数据库中分析基因表达数据.
- 使用单变量和多变量考克斯回归模型来识别和验证九个RBP签名.
- 进行了接收器操作特征 (ROC) 分析和基因组丰富分析 (GSEA).
主要成果:
- 确定了9个RBP签名 (ACO1,G3BP1,NMD3,RNGTT,ZNF385A,SARS,CARS2,YARS,SMAD6) 在OSCC中具有预后价值.
- 根据总生存期 (OS) 和无病生存期 (DFS),患者被分为高风险和低风险组.
- 高风险组显示瘤发生相关途径的丰富,包括细胞周期和ERBB信号传递.
结论:
- 一个新的,强大的九个RBP签名被开发和验证为OSCC预后.
- 这种RBP签名作为一个独立和可靠的预后生物标志物.
- 这些发现可以指导OSCC患者的临床治疗.
相关概念视频
Cancer Survival Analysis
381
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
381
mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K


